KRAS的致癌突变通过CUL3/LZTR1 E3结合酶复合体调节其周转率
Andreas Damianou1,2, Zhu Liang3,2, Frederik Lassen3,4
1Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK andreas.damianou@ndm.ox.ac.uk.
癌症中的KRAS突变破坏了其作为分子开关的功能. 这项研究表明,特定的KRAS突变会损害与LZTR1的相互作用,影响蛋白质水平,并提供潜在的治疗点.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 蛋白质组学是指蛋白质组学.
背景情况:
- 克拉斯是一种原瘤基因,在人类癌症中经常发生突变.
- 激活KRAS突变会损害GTP水解,改变信号通路.
- KRAS突变的精确下游影响仍然不完全理解.
研究的目的:
- 为了描述野生类型 (WT) 和瘤性KRAS突变的分子环境.
- 为了识别与KRAS突变物差异性相互作用的蛋白质.
- 为了研究KRAS突变对蛋白质周转的影响.
主要方法:
- 使用APEX2近距离标签来捕获KRAS交互器.
- 使用定量蛋白质组学来分析标记的蛋白质.
- 该研究将WT KRAS与G12D,G13D和Q61H突变物在不同的条件下进行了比较.
主要成果:
- 确定了已知的KRAS相互作用器,包括ARAF和LZTR1.
- 克拉斯突变 (G12D,G13D,Q61H) 取消了与LZTR1.1的关联.
- 这种干扰会影响KRAS蛋白循环.
结论:
- KRAS突变改变了其分子相互作用,影响了蛋白质的稳定性.
- 通过KRAS突变取消LZTR1关联会影响KRAS的营业额.
- 了解LZTR1介导的KRAS调节可能有助于癌症治疗.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
10:13A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
相关概念视频
The Ras Gene
Ras is a...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
MAPK Signaling Cascades
